AKT1 and neoplasm: MiR-10a increases cisplatin resistance in lung adenocarcinoma circulating tumor cells by targeting the PI3K/Akt pathway (Huang et al., 2020) and also targets TFAP2C to promote Gem resistance in PDAC (Xiong et al., 2018).